CelLBxHealth

CelLBxHealth plc has appointed Peter Collins as its new CEO and added three Non-Executive Directors to its board. This strategic realignment aims to bolster growth and governance, leveraging the Parsortix® platform for circulating tumor cell analysis. The new leadership brings diverse expertise to drive product sales, enhance lab services, and develop new tests, while investors will be watching for tangible strategic advancements.